Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)
This study aims to explore the optimal course of neoadjuvant immunotherapy for HNSCC by comparing the efficacy and safety of 4 cycles and 2 cycles of neoadjuvant tislelizumab combined with chemotherapy.
Histological or pathological diagnosis of head and neck squamous cell carcinoma; [+9]
Previously received anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody... [+14]